Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Biochem Biophys Res Commun ; 463(1-2): 148-53, 2015.
Article in English | MEDLINE | ID: mdl-26002462

ABSTRACT

We previously showed that recessive ataxic tottering-6j mice carried a base substitution (C-to-A) in the consensus splice acceptor sequence linked to exon 5 of the α1 subunit of the Cav2.1 channel gene (Cacna1a), resulting in the skipping of exon 5 and deletion of part of the S4-S5 linker, S5, and part of the S5-S6 linker in domain I of the α1 subunit of the Cav2.1 channel. However, the electrophysiological and pharmacological consequences of this mutation have not previously been investigated. Upon whole-cell patch recording of the recombinant Cav2.1 channel in heterologous reconstitution expression systems, the mutant-type channel exhibited a lower recovery time after inactivation of Ca(2+) channel current, without any change in peak current density or the current-voltage relationship. Tottering-6j mice exhibited absence-like seizures, characterized by bilateral and synchronous 5-8 Hz spike-and-wave discharges on cortical and hippocampal electroencephalograms, concomitant with sudden immobility and staring. The pharmacological profile of the seizures was similar to that of human absence epilepsy; the seizures were inhibited by ethosuximide and valproic acid, but not by phenytoin. Thus, the tottering-6j mouse is a useful model for studying Cav2.1 channel functions and Cacna1a-related diseases, including absence epilepsy.


Subject(s)
Calcium Channels, N-Type/genetics , Epilepsy, Absence/genetics , Mutation , Animals , Anticonvulsants/pharmacology , Ataxia/drug therapy , Ataxia/genetics , Ataxia/physiopathology , Calcium Channels, N-Type/physiology , Disease Models, Animal , Electroencephalography , Electrophysiological Phenomena , Epilepsy, Absence/drug therapy , Epilepsy, Absence/physiopathology , Ethosuximide/pharmacology , HEK293 Cells , Humans , Male , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Neurologic Mutants , Mutant Proteins/genetics , Mutant Proteins/physiology , Patch-Clamp Techniques , RNA, Messenger/genetics , RNA, Messenger/metabolism , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Valproic Acid/pharmacology
2.
Life Sci ; 89(21-22): 765-72, 2011 Nov 21.
Article in English | MEDLINE | ID: mdl-21971119

ABSTRACT

AIMS: GPR61 is an orphan G protein-coupled receptor whose function remains unknown. The purpose of the present study is to elucidate the importance of GPR61 in metabolism by characterization of GPR61-deficient mice. MAIN METHODS: Male GPR61-deficient mice were characterized regarding various metabolic parameters, including food intake, body weight, oxygen consumption, body temperature, locomotor activity, and in a pair feeding study. Hypothalamic gene expression was analyzed using real-time quantitative RT-PCR. KEY FINDINGS: GPR61-deficient mice exhibited marked hyperphagia and heavier body weight than wild-type mice. Hyperphagia of GPR61-deficient mice was observed before the differences in body weight became apparent between the genotypes. When body weight difference did become apparent between genotypes, increases in visceral fat pad weight, liver weight, liver triglyceride (TG) content, plasma leptin, and plasma insulin were observed in GPR61-deficient mice, suggesting that GPR61 deficiency caused obesity associated with hyperphagia. Oxygen consumption, body temperature, and locomotor activity were not significantly different between GPR61-deficient and wild-type mice. Pair-fed GPR61-deficient mice had a greater fat mass than wild-type mice despite comparable body weight in both genotypes. The mRNA levels of proopiomelanocortin (POMC) and brain-derived neurotropic factor (BDNF) in the hypothalamus of GPR61-deficient mice were significantly lower than those of wild-type mice. SIGNIFICANCE: GPR61-deficient mice exhibited obesity associated with hyperphagia. These findings suggest that GPR61 is involved in the regulation of food intake and body weight, and may be of importance when considering GPR61 as a therapeutic target for obesity or eating disorders.


Subject(s)
Receptors, G-Protein-Coupled/metabolism , Animals , Body Composition/genetics , Body Temperature/genetics , Body Weight/genetics , Calorimetry, Indirect , Diet , Eating/genetics , Galactosides , Immunohistochemistry , Indoles , Lac Operon , Liver/metabolism , Mice , Mice, Inbred C57BL , Mice, Knockout , Motor Activity/physiology , Organ Size/genetics , Oxygen Consumption/drug effects , Phenotype , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , Real-Time Polymerase Chain Reaction , Receptors, G-Protein-Coupled/genetics , Triglycerides/metabolism
3.
J Endocrinol ; 201(3): 361-7, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19332449

ABSTRACT

Glucagon-like peptide-1 (GLP-1) is an incretin hormone that potentiates insulin secretion in a glucose-dependent manner. Selective GLP-1 secretagogue would be one of the potential therapeutic targets for type 2 diabetes. Here, we describe a newly identified small molecule compound (compound A) that stimulates secretion of GLP-1 in murine enteroendocrine cell lines, STC-1 and GLUTag cells, and in primary cultured fetal rat intestinal cells (FRIC). The underlying mechanism by which compound A stimulated GLP-1 secretion was also examined. Compound A stimulated GLP-1 secretion from STC-1 cells in a concentration-dependent manner, and also from GLUTag cells and FRIC. The action of compound A was selective against other tested endocrine functions such as secretion of insulin from rat islets, growth hormone from rat pituitary gland cells, and norepinephrine from rat PC-12 cells. In STC-1 cells, the compound A-stimulated GLP-1 secretion was neither due to cyclic AMP production nor to Ca(2+) release from intracellular stores, but to extracellular Ca(2+) influx. The response was inhibited by the presence of either L-type Ca(2+) channel blockers or K(+) ionophore. Perforated-patch clamp study revealed that compound A induces membrane depolarization. These results suggest that neither Galphas- nor Galphaq-coupled signaling account for the mechanism of action, but depolarization-coupled Ca(2+) influx from extracellular space is the primary cause for the GLP-1 secretion stimulated by compound A. Identifying a specific target molecule for compound A will reveal a selective regulatory pathway that leads to depolarization-mediated GLP-1 secretion.


Subject(s)
Calcium Channel Agonists/pharmacology , Calcium/metabolism , Glucagon-Like Peptide 1/metabolism , Membrane Potentials/drug effects , Secretory Pathway/drug effects , Animals , Calcium/physiology , Calcium Channel Blockers/pharmacology , Cells, Cultured , Drug Evaluation, Preclinical , Enteroendocrine Cells/drug effects , Enteroendocrine Cells/metabolism , Female , Isoindoles/pharmacology , Male , Membrane Potentials/physiology , Mice , Oxazoles/pharmacology , PC12 Cells , Pregnancy , Rats , Rats, Wistar , Substrate Specificity , Verapamil/pharmacology
4.
Brain Res ; 1234: 59-65, 2008 Oct 09.
Article in English | MEDLINE | ID: mdl-18703034

ABSTRACT

An infant animal isolated from its mother emits vocalizations spanning from the audible to the ultrasonic. These vocalizations are believed to represent distress signals from the pup. However, the neurobiological basis for vocalizations elicited by isolation has not been well characterized under different environmental conditions. The present study was designed to clarify the role of the corticotropin-releasing factor (CRF) system in vocalizations elicited by isolating a rat pup at ambient temperatures of 37 degrees C (temperature of the nest in which the mother and littermates are present) and 24 degrees C (room temperature). Sprague-Dawley rat pups at 7 days old were isolated from their dam, then the number of vocalizations was measured for 5 min. The number of vocalizations increased when ambient temperature was changed from 37 degrees C to 24 degrees C. Systemic administration of CRF (3 or 10 mg/kg) increased the number of vocalizations at 37 degrees C in a dose-dependent manner. CRF-induced increases in the number of vocalizations at 3 mg/kg were completely blocked by a selective CRF1 receptor antagonist, NBI27914 (3 mg/kg), but not by a selective CRF2 receptor antagonist, K41498 (3 mg/kg). NBI27914 (30 mg/kg), but not K41498 (3 mg/kg), suppressed the increased number of vocalizations at 24 degrees C. These results demonstrate involvement of the CRF-CRF1 receptor regulatory system on the modulation of ultrasonic vocalizations by rat pups separated from their dam.


Subject(s)
Anxiety, Separation/psychology , Corticotropin-Releasing Hormone/pharmacology , Receptors, Corticotropin-Releasing Hormone/agonists , Vocalization, Animal/drug effects , Amphibian Proteins/pharmacology , Aniline Compounds/pharmacology , Animals , Data Interpretation, Statistical , Female , Male , Peptide Hormones/pharmacology , Pyrimidines/pharmacology , Rats , Rats, Sprague-Dawley , Receptors, Corticotropin-Releasing Hormone/antagonists & inhibitors , Skin Temperature/drug effects , Temperature
SELECTION OF CITATIONS
SEARCH DETAIL
...